TY - JOUR
T1 - Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer: Preliminary experience with clinically node negative patients after systemic treatment
AU - Sanchez, A. M.
AU - Terribile, Daniela Andreina
AU - Franco, Antonio
AU - Martullo, Annamaria
AU - Orlandi, Armando
AU - Magno, Stefano
AU - Di Leone, Alba
AU - Moschella, Francesca
AU - Natale, Maria
AU - D'archi, S.
AU - Scardina, L.
AU - Mason, Elena Jane
AU - De Lauretis, Flavia
AU - Marazzi, Fabio
AU - Masetti, Riccardo
AU - Franceschini, Gianluca
PY - 2021
Y1 - 2021
N2 - Sentinel lymph node biopsy (SLNB) following neoadjuvant treatment (NACT) has been questioned by many studies that reported heterogeneous identification (IR) and false negative rates (FNR). As a result, some patients receive axillary lymph node dissection (ALND) regardless of response to NACT, leading to a potential overtreatment. To better assess reliability and clinical significance of SLNB status on ycN0 patients, we retrospectively analyzed oncological outcomes of 399 patients treated between January 2016 and December 2019 that were either cN0-ycN0 (219 pa-tients) or cN1/2-ycN0 (180 patients). The Endpoints of our study were to assess, furthermore than IR: oncological outcomes as Overall Survival (OS); Distant Disease Free Survival (DDFS); and Regional Disease Free Survival (RDFS) according to SLNB status. SLN identification rate was 96.8% (98.2% in patients cN0-ycN0 and 95.2% in patients cN+-ycN0). A median number of three lymph nodes were identified and removed. Among cN0-ycN0 patients, 149 (68%) were confirmed ypN0(sn), whereas regarding cN1/2-ycN0 cases 86 (47.8%) confirmed an effective downstaging to ypN0. Three year OS, DDFS and RDFS were significantly related to SLNB positivity. Our data seemed to confirm SLNB feasibility following NACT in ycN0 patients, furthermore reinforcing its predictive role in a short observation timing.
AB - Sentinel lymph node biopsy (SLNB) following neoadjuvant treatment (NACT) has been questioned by many studies that reported heterogeneous identification (IR) and false negative rates (FNR). As a result, some patients receive axillary lymph node dissection (ALND) regardless of response to NACT, leading to a potential overtreatment. To better assess reliability and clinical significance of SLNB status on ycN0 patients, we retrospectively analyzed oncological outcomes of 399 patients treated between January 2016 and December 2019 that were either cN0-ycN0 (219 pa-tients) or cN1/2-ycN0 (180 patients). The Endpoints of our study were to assess, furthermore than IR: oncological outcomes as Overall Survival (OS); Distant Disease Free Survival (DDFS); and Regional Disease Free Survival (RDFS) according to SLNB status. SLN identification rate was 96.8% (98.2% in patients cN0-ycN0 and 95.2% in patients cN+-ycN0). A median number of three lymph nodes were identified and removed. Among cN0-ycN0 patients, 149 (68%) were confirmed ypN0(sn), whereas regarding cN1/2-ycN0 cases 86 (47.8%) confirmed an effective downstaging to ypN0. Three year OS, DDFS and RDFS were significantly related to SLNB positivity. Our data seemed to confirm SLNB feasibility following NACT in ycN0 patients, furthermore reinforcing its predictive role in a short observation timing.
KW - Breast cancer
KW - Locally advanced breast cancer
KW - Mini-invasive treatment
KW - Neoadjuvant chemotherapy
KW - Sentinel lymph node
KW - Systemic treatment
KW - Breast cancer
KW - Locally advanced breast cancer
KW - Mini-invasive treatment
KW - Neoadjuvant chemotherapy
KW - Sentinel lymph node
KW - Systemic treatment
UR - http://hdl.handle.net/10807/178067
U2 - 10.3390/jpm11030172
DO - 10.3390/jpm11030172
M3 - Article
SN - 2075-4426
VL - 11
SP - 1
EP - 13
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
ER -
